神经母细胞瘤分子影像与治疗的现状及未来展望
神经母细胞瘤是儿童最常见的颅外实体瘤,约半数患者诊断时已发生转移,预后差。核医学在其诊断、分期、疗效评估和长期随访中起关键作用,约90%的神经母细胞瘤对MIBG摄取阳性。123I-MIBG全身显像联合SPECT/CT是标准核医学影像技术,PET显像具有更高分辨率等优势,131I-MIBG治疗是高危患儿一线治疗的一部分。
要点
- 约90%的神经母细胞瘤对MIBG摄取阳性,123I-MIBG全身显像联合SPECT/CT是标准核医学影像技术。
- 约10%的神经母细胞瘤对MIBG不摄取,PET显像具有更高的空间和时间分辨率、灵敏度和定量能力。
- 131I-MIBG治疗是高危神经母细胞瘤患儿一线治疗的一部分。
核心结论
- 核医学在神经母细胞瘤的诊断、分期、疗效评估和长期随访中起关键作用,并在治疗中发挥重要作用。
研究设计与样本
- 本文为综述,讨论当前和新型放射性药物在神经母细胞瘤核医学显像和治疗中的应用。
主要发现
- 约90%的神经母细胞瘤对MIBG摄取阳性,约10%对MIBG不摄取。
- 123I-MIBG全身显像通常联合SPECT/CT,是神经母细胞瘤的标准核医学影像技术。
- PET显像相比SPECT具有更高的空间和时间分辨率、更高的灵敏度、更优的定量能力和全身断层显像能力。
- 131I-MIBG治疗是高危神经母细胞瘤患儿一线治疗的一部分,放射性核素标记生长抑素类似物的肽受体放射性核素治疗已成功用于神经母细胞瘤治疗。
关键数值与推荐
- 约90%的神经母细胞瘤对MIBG摄取阳性,约10%对MIBG不摄取。
- 123I-MIBG全身显像通常联合SPECT/CT,是神经母细胞瘤的标准核医学影像技术。
- 131I-MIBG治疗是高危神经母细胞瘤患儿一线治疗的一部分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neuroblastoma is the most common extracranial solid tumor in children and arises from anywhere along the sympathetic nervous system. It is a highly heterogeneous disease with a wide range of prognosis, from spontaneous regression or maturing to highly aggressive. About half of pediatric neuroblastoma patients develop the metastatic disease at diagnosis, which carries a poor prognosis. Nuclear medicine plays a pivotal role in the diagnosis, staging, response assessment, and long-term follow-up of neuroblastoma. And it has also played a prominent role in the treatment of neuroblastoma. Because the structure of metaiodobenzylguanidine (MIBG) is similar to that of norepinephrine, 90% of neuroblastomas are MIBG-avid. 123I-MIBG whole-body scintigraphy is the standard nuclear imaging technique for neuroblastoma, usually in combination with SPECT/CT. However, approximately 10% of neuroblastomas are MIBG nonavid. PET imaging has many technical advantages over SPECT imaging, such as higher spatial and temporal resolution, higher sensitivity, superior quantitative capability, and whole-body tomographic imaging. In recent years, various tracers have been used for imaging neuroblastoma with PET. The importance of patient-specific targeted radionuclide therapy for neuroblastoma therapy has also increased. 131I-MIBG therapy is part of the front-line treatment for children with high-risk neuroblastoma. And peptide receptor radionuclide therapy with radionuclide-labeled somatostatin analogues has been successfully used in the therapy of neuroblastoma. Moreover, radioimmunoimaging has important applications in the diagnosis of neuroblastoma, and radioimmunotherapy may provide a novel treatment modality against neuroblastoma. This review discusses the use of current and novel radiopharmaceuticals in nuclear medicine imaging and therapy of neuroblastoma.
引用
- Feng L, Li S, Wang C, et al. Current Status and Future Perspective on Molecular Imaging and Treatment of Neuroblastoma. Semin Nucl Med. 2023. PMID: 36682980. doi:10.1053/j.semnuclmed.2022.12.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。